Leadership & Senior Management Team
Keith F Martin, PhD, MIoD, MRPharmS – Chief Executive Officer
Keith Martin has enjoyed a successful 30+ year career in both large pharmaceutical companies and early stage biopharmaceutical companies. He has held senior positions in R&D and corporate & business development as well as both executive and non-executive Board positions with management and leadership roles in UK, Belgium, USA & Spain. He has raised more than € 40 million in equity and grants for early stage companies. In addition, Keith has developed products from bench to market and realised value through significant licensing deals as well being experienced in venture investment.
Since April 2006, he has been CEO of Apitope. He led the completion of two successful Phase I clinical trials in multiple sclerosis patients, closed the €10 million Series A (October 2008) and €12 million Series B (September 2015) financings and a €150 million+ licensing deal in January 2009.
Previously as a founder and president of KetoCytonyx Inc, he was responsible for securing seed and Series A financing of €4.6 million. Prior to that role, as BTG’s Global Director of Life Sciences, he was responsible for an extensive portfolio of product candidates and licensee marketed products. As Deputy Head of Biology at BASF Pharma, he developed six CNS compounds from the bench through to Phase I and was a key member of the team that developed two products to full market approval in USA and UK.
Keith began his research career as a PhD student at the University of Bath. He then held a Wellcome Trust Fellowship in Mental Health at Nottingham University Medical School in addition to a NATO Exchange Fellowship to Princeton University Psychology Department and has an extensive list of publications and patents.
Professor David Wraith, PhD – Chief Scientific Officer & Founder
Professor David Wraith is the CSO and founder of Apitope. He is a world leading research immunologist with over 25 years’ experience and has authored over 120 articles in peer reviewed scientific journals.
David was the Head of the Department of Pathology & Microbiology at the University of Bristol from 1996-2004. He has been awarded research fellowships by the MRC (UK), National MS Society (USA), Sidney Sussex College, Cambridge and the Wellcome Trust. He has been a member of SABs for TEVA, GSK and Peptide Therapeutics; expert advisor to Hoffman La Roche on autoimmune therapeutics; expert advisor to the DTI on Stem Cell Therapies and to the Food Standards Agency on Peanut Allergy; current member of the MRC Infections and Immunity Board; past member of research grant panels for Arthritis Research UK, MS Society, NIH, NKRF and the Wellcome Trust.
Hayley French, PhD, MSc (IP), CLP – Commercial Director & General Counsel
Hayley brings with her over fifteen years’ experience of negotiating licences and collaborations and managing alliances in the life sciences sector. Prior to joining Apitope, Hayley spent three years at Novartis, based at the Basel headquarters, where she worked closely on all global deals and collaborations in the respiratory division.
Prior to Novartis, Hayley worked in the Life Sciences Group of Bird & Bird, London, specialising in advising pharmaceutical and biotech companies. Prior to joining Bird & Bird, she was Head of Commercial Legal Affairs at the Centre for Applied Microbiology and Research (CAMR) in Salisbury, UK. Hayley started her career at University College London Ventures where she was responsible for the development, management and commercialisation of technologies in the life sciences sector.
Hayley is president of the Licensing Executives Society Britain & Ireland and vice chair of the LES International (LESI) life sciences committee. She also sits on the BIA IP advisory group. She teaches on the LESI Intellectual Asset Management courses and is a regular speaker on IP licensing and negotiation.
She has a B.Sc. in Microbiology from the University of Liverpool, as well as a PhD in Microbiology and a M.Sc. in intellectual property from the University of London and is a certified licensing professional (CLP).
Christina Carnegie MB,BS, FFPM – Chief Medical Officer
Dr Christina Carnegie trained in Anaesthesia and Intensive Care at St Bartholomew’s Hospital, London. Since leaving the NHS she has spent 30 years in the Pharmaceutical Industry and has held both executive and non-executive Board positions in the US and the UK.
For 11 years she was Medical Director of Abbott Laboratories in the UK. During this time she was responsible for the Clinical Research Operations within Great Britain and Ireland. In addition she was responsible for the Regulatory Affairs Group and had close liaison with the Regulatory Agencies in both Europe and the USA. She was also an active member of the Medical Committee of the Association of the British Pharmaceutical Industry.
Since September 2000 Christina has been an independent Consultant to 11 pharmaceutical companies including 8 start-ups in both Europe and the USA. Her activities include advising companies on their strategy for clinical development and product registration. In addition she has been actively involved in fund raising for both her clients and advising Venture Capitalists on their potential investments.
Luc Lammens – Finance & HR Director
Luc Lammens graduated as Master in Scientific Applied Economics, with specialization in International Business Affairs (K.U. Leuven 1988). He is currently a financial consultant for innovative, start up and early stage companies and is active in Corporate and Academic Spin Outs. He is in charge of specific financial missions and technology transfer projects.
Luc contributed to the start-up, financial long term planning, IFRS conversion, audit preparations and successful IPO of Movetis (100M€).
He had a pivotal role in relocating Biocartis’ R&D and Manufacturing from Lausanne to Flanders in collaboration with the Flemish regional organizations (VIB/FIT/PMV). He had the lead in the integration of the financial processes and the introduction of ERP for all Biocartis affiliates.
Luc also has an impressive record of success in obtaining grant financing for R&D from the Flemish region (>€15 million).
Previously, he spent 10 years at Janssen Pharmaceutica nv (J&J) working primarily as a financial analyst for in-licensing agreements. He was also responsible for financial control and reporting on sales and marketing departments. Prior to that, he was member of the business development group from the Belgian-Chinese Joint-Venture, Xian-Janssen. He started his career with a European sugar producer (Tiense Suikerraffinaderij – Südzucker) and a large London trading company (E.D. & F. Man).
He is the author of three books on Business Plan, Financial Plan and Venture Capital and is a contributor to the Intellectual Property Policy of the Institute for Tropical Medicine.
Lotta Jansson, PhD – Research Director
Lotta joined Apitope from Astra Zeneca where she was Associate Director in the Dept. of Neuroscience, iMed Neuroscience area in Södertälje, Sweden. In this role Lotta headed the GLP Animal Facility and her section delivered the in vivo models profiling of potential candidate drugs in the areas of pain and neurodegenerative diseases. Lotta was also a member of new target generation team focusing on the neuroimmunological mechanisms in Alzheimer’s Disease.
Lotta`s immunology career began with Prof. Hans Wigzell, Dept at Uppsala University and then the experimental rheumatology group led by Prof. Lars Klareskog characterizing collagen induced arthritis models. Her PhD thesis is focused on the immune modulatory role of sex hormones in experimental models of rheumatoid arthritis (CIA) and multiple sclerosis (EAE). In 1994 Dr. Jansson moved to the Medical Inflammation Research section at Lund University, headed by Prof. Rikard Holmdahl as Assistant Professor with focus on the immunological mechanisms and finding genes involved in peptide induced EAE.
After 5 years at Lund University she was recruited into the Dept. for Immune Pharmacology at AstraZeneca in Lund as Associate Director and an expert in in vivo experimental arthritis models and leading a group of scientists to find new therapies for rheumatoid arthritis. She also worked in gastrointestinal research as Disease Area Scientific Leader for Inflammatory Bowel Disease (IBD) with the remit to build a portfolio consisting of both small molecules and biopharmaceuticals.
During her time at Astra Zeneca in Sweden and the UK, she took three candidates from research into clinical development and has more than 40 scientific peer reviewed publications and patents.